progression-free survival Archives - Kidney Cancer Support Network

ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer

Results from the phase 3 CLEAR study, presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium over the weekend, showed that lenvatinib used in combination with either pembrolizumab or everolimus resulted in improved survival and tumour shrinkage compared to sunitinib when used as a first-line treatment for patients with advanced renal cell […]

Feb 15, 2021 / Comments Off / Sharon Kell / Tags: Afinitor, ASCO, combination therapy, everolimus, first-line treatment, Keytruda, lenvatinib, Lenvima, overall survival, pembrolizumab, progression-free survival, renal cell carcinoma

ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer

A gene called MET codes for a protein called MET tyrosine protein kinase (also called hepatocyte growth factor receptor), which stimulates the growth and development of tumours. MET tyrosine protein kinase is a key driver of the growth and development of papillary renal cell carcinoma (pRCC). In this study presented at the American Society of […]

Feb 15, 2021 / Comments Off / Sharon Kell / Tags: ASCO, c-Met inhibitor, Cabometyx, cabozantinib, crizotinib, MET, papillary RCC, progression-free survival, renal cell carcinoma, savolitinib

ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer

In a small phase 2 study presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), the novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), showed promising anti-cancer activity in combination with cabozantinib in patients with metastatic clear cell renal cell carcinoma (RCC) that had been previously treated. Kidney cancers develop […]

Feb 12, 2021 / Comments Off / Sharon Kell / Tags: ASCO, belzutifan, Cabometyx, cabozantinib, HIF-2α, MK-6482, overall survival, progression-free survival, renal cell carcinoma, safety and tolerability, side effects

ASCO GU 2021: Immunotherapy for untreated non-clear cell kidney cancer

Results of a retrospective study presented during the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) looked at the effect of immune checkpoint inhibitors (immunotherapy, e.g. nivolumab, ipilimumab, pembrolizumab) on the survival of patients with metastatic non-clear cell renal cell carcinoma (RCC) compared to targeted therapy with vascular endothelial growth factor (VEGF) […]

Feb 12, 2021 / Comments Off / Sharon Kell / Tags: ASCO, checkpoint inhibitors, immunotherapy, mTOR inhibitors, non-clear cell kidney cancer, overall survival, progression-free survival, renal cell carcinoma, response rate, VEGF inhibitors

ASCO GU 2021: Nivolumab plus cabozantinib combination for the first-line treatment of advanced kidney cancer

The past couple of years has seen a number of combination therapies for the first-line treatment of advanced/metastatic renal cell carcinoma (RCC) become available. At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco this week, ongoing results from the phase 3 CheckMate-9ER clinical trial with the nivolumab plus cabozantinib […]

Feb 09, 2021 / Comments Off / Sharon Kell / Tags: ASCO, Cabometyx, cabozantinib, combination therapy, immunotherapy, nivolumab, Opdivo, overall survival, progression-free survival, renal cell carcinoma, response rate, targeted therapy, treatments response, VEGF inhibitors

Effect of antibiotics on outcomes with systemic treatments for metastatic kidney cancer

The microbes in the gut (the gut microbiome) are a key part of our immune system. The use of antibiotics disrupts the gut microbiome and has been shown to make people susceptible to various illnesses. In this study, researchers investigated how antibiotics may influence response to treatment and clinical outcomes in people with metastatic renal […]

Feb 02, 2021 / Comments Off / Sharon Kell / Tags: antibiotics, checkpoint inhibitors, cytokines, gut microbiome, immunotherapy, microbes, mTOR inhibitors, overall survival, progression-free survival, targeted therapy

Cabozantinib plus nivolumab granted FDA approval for first-line treatment of advanced kidney cancer

The Food and Drug Administration (FDA) in the United States has approved the cabozantinib (Cabometyx) plus nivolumab (Opdivo) combination for first-line treatment of advanced renal cell carcinoma (RCC) based on the results of the Checkmate 9ER trial. Around 20-30% of people are diagnosed with advanced RCC, and 30% of people treated for early stage RCC go on […]

Jan 26, 2021 / Comments Off / Sharon Kell / Tags: Cabometyx, cabozantinib, combination therapy, FDA, nivolumab, Opdivo, overall survival, progression-free survival, renal cell carcinoma, response rate

Obesity diminishes response to immunotherapy in kidney cancer

In this study, the researchers looked at the interaction between obesity and outcomes in patients taking immune checkpoint inhibitors (anti-PD-1 immunotherapy, e.g. nivolumab, pembrolizumab) for the treatment of renal cell carcinoma (RCC). Seventy-two (72) patients with metastatic RCC were treated with anti–PD-1 immunotherapy (none had been treated with immunotherapy before). Obese patients had poorer progression-free […]

Jan 13, 2021 / Comments Off / Sharon Kell / Tags: immunotherapy, metastases, obesity, overall survival, PD-1, progression-free survival, renal cell carcinoma

Obesity and kidney cancer

A large review of the data showed that cancer specific survival and prognosis were improved in renal cell carcinoma (RCC) patients who were overweight or obese compared with patients with a normal body mass index (BMI). Data from 50,717 RCC patients were reviewed in this study. This review showed that cancer specific survival, progression-free survival […]

Jan 13, 2021 / Comments Off / Sharon Kell / Tags: cancer survival, obesity, overall survival, overweight, progression-free survival, renal cell carcinoma

Percutaneous thermoablation for small renal masses

This study looked at the survival of patients suitable for surgery who underwent percutaneous thermoablation as a first-line treatment for small renal masses (stage T1a). Eighty-five patients who were suitable for surgery were included in the study. These patients had 97 kidney masses that were proven to be malignant (cancerous) with a biopsy (T1a). These […]

Jan 07, 2021 / Comments Off / Sharon Kell / Tags: overall survival, percutaneous ablation, progression-free survival, renal cell carcinoma, small renal mass, thermoablation

Showing 1 to 10 of 91 results

TOP

Settings

Shopping Bag